{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T23:29:35Z","timestamp":1785713375924,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,7,31]],"date-time":"2011-07-31T00:00:00Z","timestamp":1312070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00405-011-1721-9","type":"journal-article","created":{"date-parts":[[2011,7,30]],"date-time":"2011-07-30T08:56:30Z","timestamp":1312016190000},"page":"531-536","source":"Crossref","is-referenced-by-count":37,"title":["A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia"],"prefix":"10.1007","volume":"269","author":[{"given":"C.","family":"Rohrmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. G.","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. S.","family":"Kuehnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,31]]},"reference":[{"key":"1721_CR1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s001060100537","volume":"50","author":"UW Geisthoff","year":"2002","unstructured":"Geisthoff UW, Schneider G, Fischinger J, Plinkert PK (2002) Heredit\u00e4re h\u00e4morrhagische Teleangiektasie (Morbus Osler). HNO 50:114\u2013128","journal-title":"HNO"},{"key":"1721_CR2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/1096-8628(20000814)93:4<320::AID-AJMG12>3.0.CO;2-R","volume":"93","author":"JE McDonald","year":"2000","unstructured":"McDonald JE, Miller FJ, Hallam SE, Nelson L, Marchuk DA, Ward KJ (2000) Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred. Am J Med Genet 93:320\u2013327","journal-title":"Am J Med Genet"},{"key":"1721_CR3","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ejhg.2009.35","volume":"17","author":"FS Govani","year":"2009","unstructured":"Govani FS, Shovlin CL (2009) Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 17:860\u2013871","journal-title":"Eur J Hum Genet"},{"key":"1721_CR4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","volume":"91","author":"CL Shovlin","year":"2000","unstructured":"Shovlin CL, Guttmacher AE, Buscarini E et al (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu\u2013Osler\u2013Weber syndrome). Am J Med Genet 91:66\u201367","journal-title":"Am J Med Genet"},{"key":"1721_CR5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2500\/ajra.2009.23.3263","volume":"23","author":"F Pagella","year":"2009","unstructured":"Pagella F, Colombo A, Matti E et al (2009) Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients. Am J Rhinol Allergy 23:52\u201358","journal-title":"Am J Rhinol Allergy"},{"key":"1721_CR6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00405-005-0956-8","volume":"263","author":"BJ Folz","year":"2006","unstructured":"Folz BJ, Zoll B, Alfke H, Toussaint A, Maier RF, Werner JA (2006) Manifestations of hereditary hemorrhagic telangiectasia in children and adolescents. Eur Arch Otorhinolaryngol 263:53\u201361","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1721_CR7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/lary.20065","volume":"119","author":"E Yaniv","year":"2009","unstructured":"Yaniv E, Preis M, Hadar T, Shvero J, Haddad M (2009) Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 119:284\u2013288","journal-title":"Laryngoscope"},{"key":"1721_CR8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1160\/TH06-07-0373","volume":"97","author":"L Fernandez","year":"2007","unstructured":"Fernandez L, Garrido-Martin EM, Sanz-Rodriguez F et al (2007) Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1\/endoglin pathway in endothelial cells. Thromb Haemost 97:254\u2013262","journal-title":"Thromb Haemost"},{"key":"1721_CR9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1017\/S0022215100136369","volume":"111","author":"VJ Lund","year":"1996","unstructured":"Lund VJ, Howard DJ (1996) Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic teleangiectasia. J Laryngol Otol 111:30\u201333","journal-title":"J Laryngol Otol"},{"key":"1721_CR10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2500\/ajr.2008.22.3145","volume":"22","author":"RJ Harvey","year":"2008","unstructured":"Harvey RJ, Kanagalingam J, Lund VJ (2008) The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Am J Rhinol 22:182\u2013187","journal-title":"Am J Rhinol"},{"key":"1721_CR11","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00405-004-0911-0","volume":"262","author":"I Karapantzos","year":"2005","unstructured":"Karapantzos I, Tsimpiris N, Goulis DG, Van Hoecke H, Van Cauwenberge P, Danielides V (2005) Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire. Eur Arch Otorhinolaryngol 262:830\u2013833","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1721_CR12","first-page":"575","volume":"22","author":"H Sadick","year":"2008","unstructured":"Sadick H, Hage J, Goessler U et al (2008) Does the genotype of HHT patients with mutations of the ENG and ACVRL1 gene correlate to different expression levels of the angiogenic factor VEGF? Int J Mol Med 22:575\u2013580","journal-title":"Int J Mol Med"},{"key":"1721_CR13","first-page":"818","volume":"90","author":"H Sadick","year":"2005","unstructured":"Sadick H, Riedel F, Naim R et al (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90:818\u2013828","journal-title":"Haematologica"},{"key":"1721_CR14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000072411","volume":"110","author":"A Cirulli","year":"2003","unstructured":"Cirulli A, Liso A, D\u2019Ovidio F et al (2003) Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 110:29\u201332","journal-title":"Acta Haematol"},{"key":"1721_CR15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3174\/ajnr.A1987","volume":"31","author":"SK Mukherji","year":"2010","unstructured":"Mukherji SK (2010) Bevacizumab (Avastin). AJNR 31:235\u2013236","journal-title":"AJNR"},{"key":"1721_CR16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.bjc.6605167","volume":"101","author":"JS Thompson Coon","year":"2009","unstructured":"Thompson Coon JS, Liu Z, Hoyle M et al (2009) Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 101:238\u2013243","journal-title":"Br J Cancer"},{"key":"1721_CR17","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1038\/eye.2008.423","volume":"23","author":"S Sacu","year":"2009","unstructured":"Sacu S, Michels S, Prager F et al (2009) Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond) 23:2223\u20132227","journal-title":"Eye (Lond)"},{"key":"1721_CR18","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","volume":"120","author":"JB Hoag","year":"2010","unstructured":"Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA (2010) An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 120:838\u2013843","journal-title":"Laryngoscope"},{"key":"1721_CR19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1177\/194589240501900515","volume":"19","author":"TS Kuehnel","year":"2005","unstructured":"Kuehnel TS, Wagner BH, Schurr CP, Strutz J (2005) Clinical strategy in hereditary hemorrhagic telangiectasia. Am J Rhinol 19:508\u2013513","journal-title":"Am J Rhinol"},{"key":"1721_CR20","first-page":"1029","volume":"146","author":"HF Dvorak","year":"1995","unstructured":"Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029\u20131039","journal-title":"Am J Pathol"},{"key":"1721_CR21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/194589240501900111","volume":"19","author":"B Folz","year":"2005","unstructured":"Folz B, Wollstein AC, Lippert BM, Werner JA (2005) Morphology and distribution of nasal telangiectasia in hht-patients with epistaxis. Am J Rhinol 19:70\u201375 (6)","journal-title":"Am J Rhinol"},{"key":"1721_CR22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/lary.20159","volume":"119","author":"J Simonds","year":"2009","unstructured":"Simonds J, Miller F, Mandel J, Davidson TM (2009) The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 119:988\u2013992","journal-title":"Laryngoscope"},{"key":"1721_CR23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ygyno.2010.02.021","volume":"117","author":"LM Randall","year":"2010","unstructured":"Randall LM, Monk BJ (2010) Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 117:497\u2013504","journal-title":"Gynecol Oncol"},{"key":"1721_CR24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/lary.21415","volume":"121","author":"TT Karnezis","year":"2011","unstructured":"Karnezis TT, Davidson TM (2011) Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 121:636\u2013638","journal-title":"Laryngoscope"},{"key":"1721_CR25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMc091271","volume":"361","author":"F Retornaz","year":"2009","unstructured":"Retornaz F, Rinaldi Y, Duvoux C (2009) More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 361:931\u2013932","journal-title":"N Engl J Med"},{"key":"1721_CR26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMc091271","volume":"361","author":"S Oosting","year":"2009","unstructured":"Oosting S, Nagengast W, de Vries E (2009) More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 361:931\u2013932","journal-title":"N Engl J Med"},{"key":"1721_CR27","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMc0901421","volume":"360","author":"P Bose","year":"2009","unstructured":"Bose P, Holter JL, Selby GB (2009) Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 360:2143\u20132144","journal-title":"N Engl J Med"},{"key":"1721_CR28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00277-006-0147-8","volume":"85","author":"D Flieger","year":"2006","unstructured":"Flieger D, Hainke S, Fischbach W (2006) Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 85:631\u2013632","journal-title":"Ann Hematol"},{"key":"1721_CR29","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMc091271","volume":"361","author":"P Bose","year":"2009","unstructured":"Bose P, Holter JL, Selby GB (2009) More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 361:931\u2013932","journal-title":"N Engl J Med"},{"key":"1721_CR30","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/lary.20757","volume":"120","author":"TM Davidson","year":"2010","unstructured":"Davidson TM, Olitsky SE, Wei JL (2010) Hereditary hemorrhagic telangiectasia\/avastin. Laryngoscope 120:432\u2013435","journal-title":"Laryngoscope"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-011-1721-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00405-011-1721-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-011-1721-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T22:03:13Z","timestamp":1592776993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00405-011-1721-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,31]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["1721"],"URL":"https:\/\/doi.org\/10.1007\/s00405-011-1721-9","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,31]]}}}